

Subgroup on Parasites Annual Report

David A. Leiby, PhD

Transmissible Diseases Department

Holland Laboratory



**American
Red Cross**

Update on SoP

- last met at ISBT Macau
- no meetings or conference calls in the interim
- remains in its infancy
- established membership
- recognized need to involve underdeveloped countries
- reviewed Chagas' testing
- developed draft questionnaire
- targeting future projects/funding

Membership

Azzedine Assal
Emma Castro
Alain Debrabant
Gilles Delage
Patrice Deletoille
Robert Duncan
Jay Epstein
Anthony Hardiman
Sanjai Kumar
José Eduardo Levi
Lily Lin
Hira Nakhasi

Silvia Sauleda Oliveras
Gerald Schochetman
Silvano Wendel
Eugene Zhiburt
Shimian Zou

Adjuncts:

Mike Busch
Roger Dodd
Susan Stramer

Underdeveloped Countries

- critical to include underdeveloped countries
 - endemic for many transfusion-transmitted parasites
 - unique challenges
 - often not adequately addressed
- suggested approaches
 - targeted surveys
 - working with regional transfusion societies
 - contacts at WHO regional offices

Chagas' Testing

- testing for 26 months in U.S.
 - significant number of confirmed positive donors
 - few confirmed transmission cases
 - considerations at upcoming BPAC for selective testing
- testing in Europe
 - limited to France and Spain
 - France:
 - 22,000 selected donors tested
 - 1 confirmed positive identified
 - Spain:
 - selective testing using 1-2 ELISAs
 - 5 cases of transfusion transmission
- Canada considering selective testing

Draft Questionnaire

- questionnaire focused on TT parasites
 - malaria, Chagas, leishmaniasis, babesiosis & other
- distributed to SoP membership for comments
- validated by selected members
- distribute in April 2009
- responses due May/June 2009
- compile and analyze data
 - volunteers?
- develop manuscript for submission to Vox

1) Cases of Transfusion Transmission

M C L B other

Historical number of cases (cumulative)

Number of cases/year

Year of last case

2) Epidemiology

M C L B other

Known species endemic to your country (list)

Known vectors endemic to your country (list)

Endemic areas in your country (provide a map)

Prevalence in population (source)

Incidence in population (source)

3) Policies to Mitigate Risk of Transmission (respond "yes" or "no")

M C L B other

Risk-Factor Questions

Blood Screening

Serologic testing (antibody)

Nucleic acid testing (NAT)

Temporary donor deferral

Length of deferral (months/years)

Re-entry criteria after deferral (e.g., absence of symptoms, negative test, etc.)

Permanent donor deferral

Are current screening interventions efficacious? (provide details)

If you do not perform any testing and a screening test was available, would your country use it for:

Donor screening?

Donor re-entry?

Both?

None?

Pathogen reduction currently in use?

If yes, what are the currently available methods (list)

In what percentage of units are these methods used?

4) Testing/Discard Rates (answer only if testing in place)

M C L B other

Number of donations tested

Number (%) positive

Discard rate

Number of donors tested

Number (%) positive

Discard rate

5) Detailed Testing Methodology (answer only if routine testing in place)

M C L B other

Screening methods available (diagnosis)

Thick smear
ELISA
Indirect Immunofluorescence Assay
Indirect Hemagglutination Assay
Complement Fixation
Latex Agglutination
Rapid Tests
Other (name)

Screening methods available (blood screening)

Thick smear
ELISA
Indirect Immunofluorescence Assay
Indirect Hemagglutination Assay
Complement Fixation
Latex Agglutination
Rapid Tests
Other (name)

Supplemental tests available

Indirect Immunofluorescence Assay
Western blot
Radioimmunoprecipitation
NAT
Other (name)

**6) Public Health Perceptions in Your Country
(high, moderate, low, very low, absent)**

M C L B other

Public health authorities priority rank in your country

Public perception rank in your country

Future Projects

- complete and analyze questionnaire
- likely will suggest new avenues for study
- apply for funding from ISBT